

## PEP-Therapy to present its first drug candidate, PEP-010, at the 2018 AACR annual meeting

**Paris (France), March 27, 2018 – PEP-Therapy, a biotechnology company which develops innovative peptides as targeted therapies for oncology, announces the presentation of preclinical data on the PEP-010 drug candidate at the upcoming American Association for Cancer Research (AACR) annual meeting, taking place from April 14 to 18 in Chicago, USA.**

Dr Sophie Lebel-Binay, Vice-President research and early clinical development at PEP-Therapy, will be presenting a poster at the AACR annual meeting in Chicago on April 17. The presentation will highlight data on PEP-010, a Cell Penetrating & Interfering Peptide. Its therapeutic properties were evaluated to demonstrate its potential as an innovative approach for breast cancers treatment. The main preclinical results demonstrated that after PEP-010 administration, significant tumor growth inhibition is observed in patient-derived xenograft (PDX) mice models of triple-negative breast cancer and hormone-positive HER2-negative breast adenocarcinoma. Formulation and pharmacokinetic (PK) studies were conducted leading to an improvement of the stability of PEP-010 and its PK parameters. To prepare GLP toxicity studies, preliminary tolerance studies were performed on mice, rats and monkeys after repeated administration of PEP-010 without demonstrating any sign of toxicity. Antoine Prestat, CEO and co-founder of PEP-Therapy, comments *"All these promising data allow to set up PEP-010 GLP toxicity studies in rodent and non-rodent species, last step before the first-in-human clinical trial"*.

### Poster presentation details

Title: PEP-010, a cell penetrating & interfering peptide as a new therapeutic approach in breast cancer

Authors: S. Lebel-Binay, F. Némati, L. Dominguez-Berrocal, J. Fleury, A. Naguez, D. Decaudin, A. Rebollo

Session Category: Experimental and Molecular Therapeutics

Session Title: Receptor Targeting and the Tumor Microenvironment

Session Date and Time: Tuesday April 17, 2018, 8:00 AM - 12:00 PM

Location: McCormick Place South, Exhibit Hall A, Poster Section 38

Poster Board Number: 4

Permanent Abstract Number: 3904

Full abstract of the presentation can be accessed on the [AACR website](#).

### **About PEP-Therapy**

PEP-Therapy is a medical biotechnology company, which develops innovative peptides as targeted therapies for oncology. PEP-Therapy operates a Cell Penetrating & Interfering Peptides (CP&IP) technology for the development of its therapeutic products. These innovative molecules penetrate cells and specifically block relevant protein-protein interactions, thus inhibiting key pathological mechanisms. Founded in January 2014, PEP-Therapy is building on research results from Inserm, Sorbonne Université and Institut Curie.

PEP-Therapy raised €2.5 M in initial funding, provided by the Quadrivium 1 seed fund, managed by Seventure Partners, and by Dr Bernard Majoie, former Chairman and CEO of Laboratoires Fournier and Founding Chairman of Fondation Fournier-Majoie pour l'Innovation (FFMI).

For more details: [www.pep-therapy.com](http://www.pep-therapy.com)

### **Contacts**

Antoine Prestat, CEO - [hello.pep@pep-therapy.com](mailto:hello.pep@pep-therapy.com) - +33(0)1 44 27 81 90